Poolbeg Pharma plc has identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with Onethree Biotech Inc.
RQ Biotechnology Ltd. (RQ Bio) has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD-3152, has entered clinical trials.
Scientists from the University of Delhi and affiliated organizations have reported the discovery and preclinical characterization of novel compounds with antiplasmodial activity.
Eurocine Vaccines AB has reported findings from preclinical studies evaluating its mRNA and protein technology platforms for its therapeutic herpes simplex virus type 2 (HSV-2) vaccine candidates. Initial results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T-cell and antibody responses.
Pfizer Inc. has acquired rights to respiratory syncytial virus (RSV) drug candidate sisunatovir from Lianbio Co. Ltd. in a deal worth up to $155 million covering development and commercialization rights in mainland China, Hong Kong, Macau and Singapore. With this agreement, Pfizer now holds global development and commercialization rights to the candidate, an orally administered fusion inhibitor is designed to block RSV replication by inhibiting F-mediated fusion with the host cell.
Jiangsu Recbio Technology Co. Ltd. has received clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC-610, from the Food and Drug Administration of the Philippines. A phase I trial will be conducted in healthy volunteers.
Symbio Pharmaceuticals Ltd. has entered into a sponsored research agreement with Tufts University to conduct joint research on the intravenous formulation of the antiviral drug brincidofovir.
RSS
